Inactive Instrument

Vitrolife AB Stock Nasdaq Stockholm

Equities

SE0000816043

Medical Equipment, Supplies & Distribution

Sales 2024 * 3.64B 333M Sales 2025 * 4.06B 372M Capitalization 22.16B 2.03B
Net income 2024 * 530M 48.55M Net income 2025 * 677M 62.01M EV / Sales 2024 * 6.3 x
Net Debt 2024 * 762M 69.75M Net cash position 2025 * 304M 27.89M EV / Sales 2025 * 5.39 x
P/E ratio 2024 *
41.8 x
P/E ratio 2025 *
32.8 x
Employees -
Yield 2024 *
0.82%
Yield 2025 *
0.85%
Free-Float 55.39%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer - 23-07-31
Director of Finance/CFO 54 21-12-31
Chairman 68 15-05-06
Members of the board TitleAgeSince
Director/Board Member 53 19-05-01
Chairman 68 15-05-06
Director/Board Member 64 18-04-26
More insiders
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Company’s product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
More about the company